A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men

Clinical Drug Investigation

Volumn 25, Issue 6, 2005, Pages 409-416

  Boydak, Bahar ^a   Nalbantgil, Sanem ^a   Fici, Francesco ^b   Nalbantgil, Istemi ^a,f   Zoghi, Mehdi ^a   Ozerkan, Filiz ^a   Tengiz, Istemihan ^c   Ercan, Erturul ^c   Yilmaz, Hasan ^d   Yoket, Umit ^e   Onder, Remzi ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Central Hospital Izmir   (Turkey)

^d Sifa Hastaneler Grubu   (Turkey)

^e SSK Egitim Hospital   (Turkey)

^f NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CHLORTALIDONE; NEBIVOLOL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL INTERCOURSE; STATISTICAL SIGNIFICANCE;

EID: 22544466994     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525060-00006     Document Type: Article

References (43)

1. Della Chiesa A, Pfiffner D, Meier B, et al. Sexual activity in hypertensive men. J Hum Hypertens 2003; 17 (8): 515-21
2. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals' follow-up study. Ann Intern Med 2003; 139 (3): 161-8
3. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164 (4): 1188-91
4. Jensen J, Lendorf A, Stimpel H, et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999; 12 (3): 271-5
5. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163 (2): 460-3
6. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342 (24): 1802-13
7. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (3): 351-7
8. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58 (3): 177-80
9. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11 (10): 1244-7
10. Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991; 151 (12): 2402-8
11. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991; 114 (8): 613-20
12. Opie LH. Diuretic downsides: but in low doses they still seem among the best authenticated antihypertensives. Cardiovasc Drugs Ther 2000; 14 (4): 407-9
13. Grimm Jr RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29 (1 Pt 1): 8-14
14. Anonymous. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
15. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206-52
16. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert concensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25 (15): 1341-62
17. Barksdale JD, Gardner SF. The impact of first-line antihyperteninsive drugs on erectile dysfunction. Pharmacotherapy 1999; 19 (5): 573-81
18. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21 (6): 377-93
19. Bansal S. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension 1988; 12 (1): 1-10
20. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997; 1: 47-51
21. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326 (2): 90-4
22. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003; 170 (2 Pt 2): S6-13
23. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, endothelidouble-blind, crossover study. Circulation 2001; 104 (5): 511-4
24. Ignarro LJ, Byrns RE, Trinh K, et al. Nebivolol: a selective beta (1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechavascular nisms. Nitric Oxide 2002; 7 (2): 75-82
25. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an Lsis arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274 (3): 1067-71
26. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003; 100 (3): 215-34
27. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol 1990; 30 (3): 353-64
28. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14 (1): 27-31
29. Williams GH. Assessing patient wellness: new perspectives on quality of life and compliance. Am J Hypertens 1998; 11 (11 Pt 2): 186S-91S
30. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57 (4): 633-51
31. Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003; 2: 35-40
32. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity antihypertenin hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11 (11): 753-7
33. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998; 12 (2): 135-40
34. Makolkin VI, Akhmedova OO, Buval'tsev VI, et al. Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes. Kardiologiia 2003; 43 (2): 40-3
35. Van Nueten L, Dupont AG, Vertommen C, et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997; 11 (2): 139-44
36. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24 (21): 1928-32
37. Panza JA, Quyyumi AA, Brush Jr JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323 (1): 22-7
38. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87 (5): 1468-74
39. Forte P, Copland M, Smith LM, et al. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349 (9055): 837-42
40. Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation 2001; 104 (6): 735-40
41. Vicaut E. Hypertension and the microcirculation. Arch Mal Coeur Vaiss 2003; 96 (9): 893-903
42. deGroat WC, Booth AM. Physiology of male sexual function. Ann Intern Med 1980; 92 (2 Pt 2): 329-31
43. Mangrella M, Rossi F, Fici F. Pharmacology of nebivolol. Pharmacol Res 1998; 38 (6): 419-31